布莱蒂拉条状多糖通过促进C/EBPε-依赖的造血复合来缓解中性缺陷症
Yaru Cui1,2,3, Yingying Luo1,2,3, Cheng Zhang3
1National Pharmaceutical Engineering Center for Solid Preparation in Chinese Herbal Medicine, Jiangxi University of Chinese Medicine, Nanchang 330006, China.
Cells
|December 10, 2025
概括
布莱蒂拉条纹多糖 (BSP) 通过增强血造干细胞功能,加速化学疗法诱导的中性粒细胞恢复. 这项研究确定C/EBPε是关键的调解者,强调BSP是中性质衰竭的潜在治疗方法.
科学领域:
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 中性是常见的化疗并发症,需要快速的中性粒细胞再生来治疗患者.
- 布莱蒂拉条纹多糖 (BSP) 显示出治疗前景,但其潜在的机制和分子标尚未完全理解.
研究的目的:
- 阐明BSP促进化学疗法诱导的中性细胞衰竭 (CIN) 中性细胞恢复的机制.
- 为了确定负责BSP的造血效应的分子点.
主要方法:
- 利用循环胺诱导的中性病小鼠模型来评估BSP的疗效.
- 在体外和体内研究了BSP对造血干细胞和原生细胞 (HSPC) 的影响.
- 采用PCR阵列分析和C/EBPε淘汰/淘汰模型来确定分子调解.
主要成果:
- 在CIN小鼠中,BSP加速了白细胞和中性粒细胞的恢复,保持了细胞活动并降低了死亡率.
- BSP增强了HSPC的重新填充,促进了细胞循环的进入,增加了特定的祖先子集.
- BSP的效果取决于C/EBPε,其淘汰或淘汰取消了BSP的治疗效益.
结论:
- 在化疗诱导的中性病症中,BSP有效促进中性粒细胞的再生.
- 转录因子C/EBPε被确定为BSP的造血复原功能的关键调解者.
- BSP代表了一种有前途的治疗策略,用于管理化疗引起的中性质减退症.
相关概念视频
Cell Specific Gene Expression
Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...
Glucose Transporters
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Drugs for Treatment of Constipation-Predominant IBS
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...


